Joint injection shows promise for stopping repeat bleeds in hemophilia

NCT ID NCT07187661

Completed Disease control Sponsor: Khyber Medical University Peshawar Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether injecting bevacizumab (a drug that blocks blood vessel growth) into the joints of people with hemophilia can prevent repeated bleeding episodes. Eighteen participants with chronic synovitis (joint inflammation) received the injection. Researchers measured changes in bleeding rates, joint health, and MRI scans over three months to see if the treatment reduced bleeds and improved joint condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin), a drug that blocks blood vessel growth
What this could lead to: If it works, this could offer a new way to reduce painful joint bleeds and improve joint health in people with hemophilia.
What could go wrong: This is a very small, early study with only 18 people and no comparison group. The effects may not be confirmed in larger trials, and there is a risk of side effects from the injection or the drug itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC SYNOVITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A synovitis hemarthrosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC SYNOVITIS HEMOPHILIA

Contacts and locations

Locations

Hayatabad Medical Complex

Peshawar, KPK, 25000, Pakistan
Institute of Pathology and Diagnostic Medicine (IPDM)

Peshawar, KPK, 25000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.